



(51) International Patent Classification:

C12N 5/07 (2010.01) C12N 9/10 (2006.01)
C12N 5/073 (2010.01) A61K 35/12 (2015.01)
C12N 5/077 (2010.01) A61K 35/30 (2015.01)
C12N 5/078 (2010.01) A61K 35/35 (2015.01)
C12N 5/079 (2010.01) A61K 35/407 (2015.01)

(21) International Application Number:

PCT/US2015/039370

(22) International Filing Date:

7 July 2015 (07.07.2015)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:


62/021,328 7 July 2014 (07.07.2014) US

(71) Applicant: TARGAZYME, INC. [US/US]; 2100 Palomar
Airport Road, Suite 214-23, Carlsbad, CA 92011 (US).(72) Inventor: WOLFE, Stephen, D.; 18301 Clear Smoke Rd.,
Boysds, MD 20841 (US).(74) Agent: HESTER, Kathryn, L.; Dunlap Codding, P.C.,
P.O. Box 16370, Oklahoma City, OK 73113-2370 (US).(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG,
MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM,
PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC,
SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,
SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
— with sequence listing part of description (Rule 5.2(a))

(54) Title: MANUFACTURE AND CRYOPRESERVATION OF FUCOSYLATED CELLS FOR THERAPEUTIC USE



(57) Abstract: Compositions for and methods of manufacturing a fucosylated cell population are provided. The method may include expansion of the cells and/or cryopreservation of the cells under conditions that retain optimum levels of cell surface fucosylation.